What Is EU GMP Annex 1 and What Does It Require?

EU GMP Annex 1 is the European guideline on the manufacture of sterile medicinal products. The revised version, effective from 2023, sets out how sterile products must be made to prevent microbial, particulate and pyrogen contamination. Its central requirement is a documented, risk-based Contamination Control Strategy (CCS) that shows how every source of contamination at a site is identified, controlled and verified.

What EU GMP Annex 1 requires

Annex 1 sets out a connected set of requirements:

• A holistic, documented Contamination Control Strategy (CCS).

• Formal application of quality risk management.

• Defined cleanroom classification and monitoring.

• Qualified barrier or isolator technology where appropriate.

• Robust aseptic process simulations.

• Clear control of personnel, utilities and equipment.

It expects these controls to be connected, not managed in isolation.

Why Annex 1 matters beyond sterile manufacturing

Although Annex 1 governs sterile products, its principles, especially the Contamination Control Strategy and risk-based thinking, are increasingly applied to non-sterile, API and OSD sites. Inspectors now expect the same discipline: controls tied to assessed risks, with evidence that they work.

Common Annex 1 challenges

Sites often struggle to move from a document that names a CCS to a strategy that genuinely governs decisions. Other frequent gaps include weak links between risk assessments and monitoring, aseptic process simulations that do not reflect the hardest real conditions, and controls that are validated but not maintained.

Frequently asked questions

When did the revised EU GMP Annex 1 take effect?

The revised Annex 1 was published in 2022 and became effective in August 2023, with one provision on lyophilisation applying from August 2024.

What is a Contamination Control Strategy under Annex 1?

It is a documented, risk-based plan describing how a site identifies and controls every source of contamination, required by Annex 1 for sterile manufacturing.

Does Annex 1 apply to non-sterile manufacturing?

Formally it governs sterile products, but its risk-based principles and CCS approach are increasingly expected across non-sterile, API and OSD sites.

About the author

Kieran Falvey is Founder and Managing Director of Pharmalliance Consulting Ltd and the creator of Contamination Control by Design (CCbD). He has more than 20 years designing, building and running pharmaceutical facilities worldwide, across FDA, EMA, TGA, PIC/S and Indian FDA (CDSCO) jurisdictions. Global expert in cGMP Compliance, Remediation and Contamination Control, helping Sterile, Non-Sterile, ATMP and Cosmetic companies navigate cGMP compliance issues.

About Pharmalliance Consulting

Pharmalliance Consulting is a GMP compliance consultancy serving pharmaceutical, sterile, non-sterile, OSD, ATMP and cosmetic manufacturers in Ireland, the UK, the EU and the US. It helps sites identify and remediate GMP risks across facilities, quality systems and contamination control, aligned with HPRA, MHRA, EMA and FDA expectations, turning findings into defensible, inspection-ready practice.

Aligning your site with EU GMP Annex 1? Explore our Contamination Control by Design approach and Contamination Prevention services, or contact the team.